Covid-19: What you need to know about Gilead's forthcoming data on an experimental drug

Results from the first clinical trial to test Gilead's drug remdesivir for Covid-19 should be coming out this month. But what exactly will these results mean for patients? STAT reporters have put together a handy guide on how to make sense of the data, including how the drug works, how the trial is being conducted, and how Gilead is likely to deal with a surge in demand if remdesivir is proven to be effective. Read more here. 

• African Americans seem to be disproportionately affected by Covid-19, according to emerging statistics. Black people make up around 15% of the population in states such as Michigan and Illinois, but also around 40% of the deaths from Covid-19. STAT's Elizabeth Cooney has more here. 
• In a new column, STAT's Matthew Herper gives the U.S. a "D-" in the way it has been handling the fight against Covid-19. He writes that the grade stands for "disorganization," but, encouragingly, that it can be fixed.
• STAT's Ed Silverman spoke with Axcella Health's Paul Fehlner, who wants to start a public company that would work on repurposing generic drugs for Covid-19. Read their conversation here. 
• Laurent Hébert-Dufresne and Vicky Chuqiao Yang write in a new STAT First Opinion that although misinformation about the coronavirus can be harmful, such information is now part of the emergency and can inform responses to crises in the future.